Matthew Brian Robers

Matthew Brian Robers

Auto-generated profile, based on publicly available information

Matthew Brian Robers

Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Cell Chemical Biology
Verified
Journal Article
Open access
JVJames D. Vasta
James D. Vasta
CCCesear R. Corona
Cesear R. Corona
JWJennifer Wilkinson
Jennifer Wilkinson
CZChad A. Zimprich
Chad A. Zimprich
JHJames R. Hartnett
James R. Hartnett
MRMatthew B. Robers
Matthew B. Robers
For kinase inhibitors, intracellular target selectivity is fundamental to pharmacological mechanism. Although a number of acellular techniques have been developed to measure kinase binding or enzymatic inhibition, such approaches can fail to accurately predict engagement in cells. Here we report the application of an energy transfer technique that enabled the first broad-spectrum, equilibrium-based approach to quantitatively profile target occupancy and compound affinity in live cells. Using this method, we performed a selectivity profiling for clinically relevant kinase inhibitors against 178 full-length kinases, and a mechanistic interrogation of the potency offsets observed between cellular and biochemical analysis. For the multikinase inhibitor crizotinib, our approach accurately predicted cellular potency and revealed improved target selectivity compared with biochemical measurements. Due to cellular ATP, a number of putative crizotinib targets are unexpectedly disengaged in live cells at a clinically relevant drug dose.

2 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CWCarrow Wells
Carrow Wells
JVJames D. Vasta
James D. Vasta
CCCesear R. Corona
Cesear R. Corona
JWJennifer Wilkinson
Jennifer Wilkinson
CZChad A. Zimprich
Chad A. Zimprich
MRMatthew B. Robers
Matthew B. Robers
Concerted multidisciplinary efforts have led to the development of Cyclin-Dependent Kinase inhibitors (CDKi’s) as small molecule drugs and chemical probes of intracellular CDK function. However, conflicting data has been reported on the inhibitory potency of CDKi’s and a systematic characterization of affinity and selectivity against intracellular CDKs is lacking. We have developed a panel of cell-permeable energy transfer probes to quantify target occupancy for all 21 human CDKs in live cells, and present a comprehensive evaluation of intracellular isozyme potency and selectivity for a collection of 46 clinically-advanced CDKi’s and tool molecules. We observed unexpected intracellular activity profiles for a number of CDKi’s, offering avenues for repurposing of highly potent molecules as probes for previously unreported targets. Overall, we provide a broadly applicable method for evaluating the selectivity of CDK inhibitors in living cells, and present a refined set of tool molecules to study CDK function.

21 March 2022 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
JVJames D. Vasta
James D. Vasta
DPD. Matthew Peacock
D. Matthew Peacock
QZQinheng Zheng
Qinheng Zheng
JWJoel A. Walker
Joel A. Walker
ZZZiyang Zhang
Ziyang Zhang
KSKevan M. Shokat
Kevan M. Shokat
Current small-molecule inhibitors of KRAS(G12C) bind irreversibly in the switch-II pocket (SII-P), exploiting the strong nucleophilicity of the acquired cysteine as well as the preponderance of the GDP-bound form of this mutant. Nevertheless, many oncogenic KRAS mutants lack these two features, and it remains unknown whether targeting the SII-P is a practical therapeutic approach for KRAS mutants beyond G12C. Here we use NMR spectroscopy and a cellular KRAS engagement assay to address this question by examining a collection of SII-P ligands from the literature and from our own laboratory. We show that the SII-Ps of many KRAS hotspot (G12, G13, Q61) mutants are accessible using noncovalent ligands, and that this accessibility is not necessarily coupled to the GDP state of KRAS. The results we describe here emphasize the SII-P as a privileged drug-binding site on KRAS and unveil new therapeutic opportunities in RAS-driven cancer.

20 June 2020 in Annual Review of Biochemistry
Verified
Journal Article
Closed access
MRM.B. Robers
M.B. Robers
Rachel Friedman OhanaRachel Friedman Ohana
Rachel Friedman Ohana
KHK.V.M. Huber
K.V.M. Huber
LKLaura Kilpatrick
Laura Kilpatrick
JVJ.D. Vasta
J.D. Vasta
KWK.V. Wood
K.V. Wood
The binding affinity and kinetics of target engagement are fundamental to establishing structure–activity relationships (SARs) for prospective therapeutic agents. Enhancing these binding parameters for operative targets, while minimizing binding to off-target sites, can translate to improved drug efficacy and a widened therapeutic window. Compound activity is typically assessed through modulation of an observed phenotype in cultured cells. Quantifying the corresponding binding properties under common cellular conditions can provide more meaningful interpretation of the cellular SAR analysis. Consequently, methods for assessing drug binding in living cells have advanced and are now integral to medicinal chemistry workflows. In this review, we survey key technological advancements that support quantitative assessments of target occupancy in cultured cells, emphasizing generalizable methodologies able to deliver analytical precision that heretofore required reductionist biochemical approaches.

6 December 2018
Verified
Book Chapter
Open access
PDF file
MRMatthew B. Robers
Matthew B. Robers
JVJames D. Vasta
James D. Vasta
CCCesear R. Corona
Cesear R. Corona
RORachel Friedman Ohana
Rachel Friedman Ohana
RHRobin Hurst
Robin Hurst
KWKeith V. Wood
Keith V. Wood
Intracellular target affinity and residence time are fundamental aspects of pharmacological mechanism (Lu and Tonge, Curr Opin Chem Biol 14:467–474, 2010). Although various robust biochemical approaches exist to measure these binding characteristics, analysis of compound binding with isolated targets may not accurately reflect engagement in the milieu of living cells. To realize the influence of cellular context, methods are needed that are capable of quantifying affinity and residence time in the presence of the intracellular factors that may impact target engagement. Bioluminescence resonance energy transfer (BRET) offers a solution for intracellular target engagement when quantitative metrics or kinetic analyses are required.

15 September 2021 in STAR Protocols
Verified
Journal Article
Open access
MRMatthew B. Robers
Matthew B. Robers
JWJennifer M. Wilkinson
Jennifer M. Wilkinson
JVJames D. Vasta
James D. Vasta
LBLena Marie Berger
Lena Marie Berger
Benedict-Tilman BergerBenedict-Tilman Berger
Benedict-Tilman Berger
SKStefan Knapp
Stefan Knapp
This protocol is used to profile the engagement of kinase inhibitors across nearly 200 kinases in a live-cell context. This protocol utilizes one single kinase tracer (NanoBRET(TM) Tracer K10) that operates quantitatively at four different concentrations. Minimizing the number of tracers offers a significant workflow improvement over the previous protocol that utilized a combination of 6 tracers. Each NanoBRET(TM) kinase assay is built using commercially available plasmids and has been optimized for NanoLuc tagging orientation, diluent DNA, and tracer concentration.